[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100330371":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":70,"collaborators":39,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":39,"enrollmentInfo":82,"targetDuration":39,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":47,"whyStopped":39,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"1 hour infusion","ACTIVE_COMPARATOR","The first group corresponds to 1-hour infusion : First administration of ceftolozane-tazobactam with 2000 mg by infusion for 60 minutes every 8 hours.\n\n24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48.",[13],"Drug: 1 hour infusion",{"label":15,"type":16,"description":17,"interventionNames":18},"4 hours infusion","EXPERIMENTAL","The second group corresponds to 4-hours infusion: First administration of ceftolozane-tazobactam with 2000 mg by infusion for 4 hours every 8 hours. 24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48.\n\n.",[19],"Drug: 4 hours infusion",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 60 minutes every 8 hours.",[9],[26],"Zerbaxa 1 g\u002F0.5 g powder",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 4 hours every 8 hours",[15],[26],[32],{"name":33,"affiliation":5,"role":34},"Stéphanie RUIZ, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":33,"role":37,"phone":38,"phoneExt":39,"email":40},"CONTACT","0561777032",null,"ruiz.s@chu-toulouse.fr",{"name":42,"role":37,"phone":39,"phoneExt":39,"email":43},"Nathalie ROQUES","roques.n@chu-toulouse.fr",[45],{"facility":46,"status":47,"city":48,"state":39,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Service Réanimation Polyvalente - CHU Rangueil","RECRUITING","Toulouse","31059","France","FR",{"type":53,"coordinates":54},"Point",[55,56],1.44367,43.60426,{"lat":56,"lon":55},[59,63,65,66,68],{"name":33,"role":37,"phone":60,"phoneExt":61,"email":62},"05 61 32 44 64","33","Ruiz.stephanie@chu-toulouse.fr",{"name":64,"role":37,"phone":39,"phoneExt":39,"email":39},"Bernard GEORGES, MD",{"name":33,"role":37,"phone":39,"phoneExt":39,"email":39},{"name":67,"role":37,"phone":39,"phoneExt":39,"email":39},"Jean-Marie CONIL, MD",{"name":69,"role":37,"phone":39,"phoneExt":39,"email":39},"David ROUSSET",{"type":71,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100330371","phase-3-short-infusion-versus-prolonged-infusion-of-ceftolozane-tazobactam-among-patients-with-ventilator-associated-pneumonia-100330371",false,"NCT03581370","Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia","Comparison of Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia to Pseudomonas Aeruginosa in Intensive Care Units","CEFTOREA","inclusion criteria\n\n* patients with ventilator associated-pneumonia to Pseudomonas aeruginosa\n* patients hospitalized in intensive care units\n* Pseudomonas aeruginosa susceptible to ceftolozane-tazobactam\n* Simplified Acute Physiological Score II (SAPS II () \\> 20\n* Expected duration of survival \\> 7 days\n* Informed consent of the patient or, failing that, the patient's close or trustworthy person\n* Affiliated to a social security scheme or equivalent\n\nNon inclusion criteria:\n\n* history of allergy to one of the two molecules\n* history of allergy to betalactamines\n* Strain Isolated resistant to Ceftolozane-Tazobactam combination\n* Renal insufficiency with a glomerular filtration rate evaluated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) \\\u003C 50 ml\u002Fmin\n* Patient on dialysis or under continuous hemodiafiltration\n* pregnant or nursing women\n* patient benefiting from a system of legal protection for adults\n* patient with active immunodepression.","ALL","18 Years",{"count":83,"type":84},80,"ESTIMATED","INTERVENTIONAL",[87],"PHASE3","The main objective of this study is to compare the median exposures at pharmacokinetic equilibrium of the two modalities of administration: 4-hours infusion of ceftolozane-tazobactam at a dosage of 2 gram three times a day vs 1-hour infusion of 2 gram three times a day.",[90],"Ventilator-associated Pneumonia",[92,93,94],"Pneumonia","Pseudomonas aeruginosa","pharmacokinetics","2024-09-23",{"date":97,"type":98},"2024-09-25","ACTUAL",{"date":100,"type":98},"2018-09-20",{"date":102,"type":84},"2025-02",{"name":5,"class":6},1]